Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)

NCT04354961 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT04354961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04354961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
May 7, 2021
Completion date
June 30, 2025
Enrollment
13 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary adenosquamous carcinoma